All In Biotech

Drug Trial Radar · NCT07100782

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Aug 2028

Study completion Sep 2028

Sponsor

Lead sponsor
University of MichiganAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.

Conditions

  • Endometriosis
  • Pelvic Pain

Interventions

  • Relugolix CTDrug

    Study medication will be provided by Sumitomo in pill bottles containing an 84-day supply of relugolix 40mg, estradiol 1mg, norethindrone acetate 0.5mg (Relugolix Combination therapy).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change score in lipopolysaccharide (LPS)-stimulated Macrophage inflammatory protein-1 alpha (MIP1-α) levelsTime frame: baseline and week 12 visit
  2. Change score for functional magnetic resonance imaging (fMRI) connectivity of the somatosensory cortices to the default-mode networkTime frame: baseline and week 12 visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.